XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.

Moderna stock is lone omen of bird flu pandemic



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>RPT-BREAKINGVIEWS-Moderna stock is lone omen of bird flu pandemic</title></head><body>

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

By Robert Cyran

NEW YORK, June 17 (Reuters Breakingviews) -The recent rise of Moderna’s MRNA.O stock tells a grim tale. The $56 billion company which pioneered a Covid vaccine has seen its market value rise 40% since the discovery of bird flu in American cows in March. The benefit to Moderna of a new outbreak is probably far less.

The H5N1 flu that’s common in various animals might mutate to spread between humans. Influenzas have a history of making such jumps. About half of the hundreds of people diagnosed since 2003 have died. This virulence can’t be assumed, however, as mild cases have been missed and the virus will change. Likewise, the odds of a strain spreading easily, and when, are impossible to predict.

More certain is the value of Moderna’s mRNA technology, which uses a virus’ genetic code to instruct the body to make antibodies. The company and its German rival BioNTech BNTX.O developed effective Covid vaccines faster than traditional methods. MRNA vaccines may have another edge. Traditional inoculations use inactivated virus, grown in fertilized eggs. The U.S. government even keeps a secret hoard of hens to ensure millions of eggs are available. The problem is that avian flu might kill fertilized eggs, hampering production.

The value to society could be vast. The International Monetary Fund estimated in 2022 that the economic damage from Covid would exceed $12.5 trillion. The tab for a more deadly bird flu could be higher, and a vaccine might slash trillions off this tab.

That’s why governments are stockpiling vaccines. The U.S. agreed to buy 4.8 million doses from Australia’s CSL CSL.AX. If Uncle Sam buys a similar amount from Moderna, and pays a rich $100 a shot, that’s $500 million of revenue. These vaccines may be a poor match against a pandemic strain, so governments are reluctant to buy too many.

A pandemic opportunity would be larger. Moderna and Pfizer PFE.N sold about $130 billion of Covid vaccines during the pandemic. Assume similar total revenue, that Pfizer takes half, and Moderna’s net margin is 66%, the same as in 2021. The company’s profit would be $43 billion.

But if the chance of an outbreak is 33%, the boost to Moderna’s bottom line falls to $14 billion - less than the increase in its market value since March. Other firms may grab a share of sales.

Post pandemic, global flu shot sales would probably be similar as today, or $7 billion annually. Moderna has planned for years to sell influenza vaccines. So this opportunity presumably was already reflected in its valuation.

It’s striking that other stocks are not pricing in the possibility of a pandemic. Pfizer’s valuation hasn’t changed much since March, and shares in prior pandemic winners such as exercise bike firm Peloton Interactive PTON.O and communications company Zoom Video Communications ZM.O are down. Moderna is a lone omen.

Follow @rob_cyran on X

CONTEXT NEWS

The U.S. Centers for Disease Control and Prevention said that as of June 10, there is an ongoing multi-state outbreak of H5N1 avian influenza in dairy cows.

Three U.S. cases of the disease have been diagnosed in humans following exposure to infected cows.


Moderna's stock flies on bird flu fears https://reut.rs/3XszV17


Editing by Peter Thal Larsen and Pranav Kiran

</body></html>

면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.

온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.

이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.

리스크 경고: 고객님의 자본이 위험에 노출 될 수 있습니다. 레버리지 상품은 모든 분들에게 적합하지 않을수 있습니다. 당사의 리스크 공시를 참고하시기 바랍니다.